The Moscow Endocrine Plant will soon begin production of two new anaesthesia drugs, according to Denis Protsenko, director of Moscow’s multidisciplinary clinical center Kommunarka, who posted the news in his Telegram channel.
The company will release 25,000 vials of its new opioid analgesic, Remifentanil (2 mg), by the end of 2025.
Protsenko did not specify the start date for the production of the intrathecal morphine drug. “Intrathecal administration is a method of delivering medication directly into the spinal canal. This method is used to help patients with severe chronic pain that cannot be relieved by other treatments, as well as to perform spinal anesthesia during various surgical procedures,” he noted. According to the specialist, the launch of the drug will provide patients with cancer and other serious illnesses an effective means to manage their pain. It will also contribute to the development of Russia’s pharmaceutical industry.
Protsenko believes that the emergence of new drugs will not only enhance the quality of medical care but also reduce Russia’s reliance on foreign supplies for doctors and patients alike.
GxP News previously reported that clinical trials are beginning in Russia for a powerful painkiller derived from a sea anemone peptide. The innovative drug molecule blocks pain on par with opioid drugs without being addictive.
